Evidence map›Paper›PMID 26870797›Full record

ArticleEBioMedicine2015

Mimecan, a Hormone Abundantly Expressed in Adipose Tissue, Reduced Food Intake Independently of Leptin Signaling.

Huang-Ming Cao, Xiao-Ping Ye, Jun-Hua Ma, He Jiang, Sheng-Xian Li, Rong-Ying Li, Xue-Song Li, Cui-Cui Guo, Zhi-Quan Wang, Ming Zhan and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EBioMedicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Huang-Ming CaoState Key Laboratory of Medical Genomics, Molecular Medicine Center, Shanghai Institute of Endocrinology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China.
Xiao-Ping YeState Key Laboratory of Medical Genomics, Molecular Medicine Center, Shanghai Institute of Endocrinology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China; Medical Center of Clinical Research, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200011, China.
Jun-Hua MaState Key Laboratory of Medical Genomics, Molecular Medicine Center, Shanghai Institute of Endocrinology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China.
He JiangState Key Laboratory of Medical Genomics, Molecular Medicine Center, Shanghai Institute of Endocrinology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China.
Sheng-Xian LiState Key Laboratory of Medical Genomics, Molecular Medicine Center, Shanghai Institute of Endocrinology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China.
Rong-Ying LiState Key Laboratory of Medical Genomics, Molecular Medicine Center, Shanghai Institute of Endocrinology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China.
Xue-Song LiState Key Laboratory of Medical Genomics, Molecular Medicine Center, Shanghai Institute of Endocrinology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China.
Cui-Cui GuoState Key Laboratory of Medical Genomics, Molecular Medicine Center, Shanghai Institute of Endocrinology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China.
Zhi-Quan WangState Key Laboratory of Medical Genomics, Molecular Medicine Center, Shanghai Institute of Endocrinology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China.
Ming ZhanState Key Laboratory of Medical Genomics, Molecular Medicine Center, Shanghai Institute of Endocrinology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China.
Chun-Lin ZuoState Key Laboratory of Medical Genomics, Molecular Medicine Center, Shanghai Institute of Endocrinology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China.
Chun-Ming PanState Key Laboratory of Medical Genomics, Molecular Medicine Center, Shanghai Institute of Endocrinology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China.
Shuang-Xia ZhaoState Key Laboratory of Medical Genomics, Molecular Medicine Center, Shanghai Institute of Endocrinology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China.
Cui-Xia ZhengMedical Center of Clinical Research, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200011, China.
Huai-Dong SongState Key Laboratory of Medical Genomics, Molecular Medicine Center, Shanghai Institute of Endocrinology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China; Medical Center of Clinical Research, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200011, China.
Ruijin Hospital · CNShanghai Ninth People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adipokines such as leptin play important roles in the regulation of energy metabolism, particularly in the control of appetite. Here, we describe a hormone, mimecan, which is abundantly expressed in adipose tissue. Mimecan was observed to inhibit food intake and reduce body weight in mice. Intraperitoneal injection of a mimecan-maltose binding protein (-MBP) complex inhibited food intake in C57BL/6J mice, which was attenuated by pretreatment with polyclonal antibody against mimecan. Notably, mimecan-MBP also induced anorexia in A(y)/a and db/db mice. Furthermore, the expression of interleukin (IL)-1β and IL-6 was up-regulated in the hypothalamus by mimecan-MBP, as well as in N9 microglia cells by recombinant mouse mimecan. Taken together, the results suggest that mimecan is a satiety hormone in adipose tissue, and that mimecan inhibits food intake independently of leptin signaling by inducing IL-1β and IL-6 expression in the hypothalamus.

Indexed as

Gene ExpressionSignal TransductionAdipose TissueAnimalsBody WeightEatingHumansHypothalamusIntercellular Signaling Peptides and ProteinsInterleukin-1betaInterleukin-6LeptinMiceMice, KnockoutMicrogliaRatsIntercellular Signaling Peptides and ProteinsInterleukin-1betaInterleukin-6LeptinOGN protein, humanAnorexiaIL-1βIL-6LeptinMimecan

Identifiers

PMID26870797
PMCPMC4740298
OpenAlexW1802642998

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.